Shares in major pharmaceutical companies fell on Thursday, after the US government said it would abandon a proposal to require health insurers to pass significant rebates on to Medicare patients.
Drugmakers are estimated to pay out in excess of $100 billion per year in rebates, with Pharmacy Benefit Managers (PBM) the primary beneficiaries.
Companies which negotiate discounts with drugmakers will be allowed to continue benefiting from those rebates.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze